Clinical trial
A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
NCT05919095 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2023
- Completion date
- June 30, 2026
- Enrollment
- 37 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
unresectable gallbladder cancer